Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip (ECHODIAH)
Evaluation of the CHOndromodulating Effect of DIAcerein in Osteoarthritis of the Hip. ECHODIAH.
We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to:
- evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis
- to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis
This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amiens, France, 80030
- Hôpital Nord
-
Bordeaux, France, 33076
- Hôpital Pellegrin
-
Boulogne, France, 92100
- Hôpital Ambroise Paré
-
Caen, France, 14033
- CHU côte de Nacre
-
Créteil, France, 94000
- Hopital Mondor
-
Dijon, France, 21000
- Hôpital Général
-
Grenoble, France, 38043
- CHU
-
Lille, France, 59037
- Hôpital Roger Salengro
-
Limoges, France, 87042
- CHRU Dupuytren
-
Marseille, France, 13 385
- Hôpital de la Timone
-
Montpellier, France, 34295
- Hopital Lapeyronie
-
Nice, France, 6202
- Hôpital de l'Archet
-
Paris, France, 75014
- Hôpital Cochin
-
Paris, France, 75011
-
Paris, France, 75674
- Hôpital Léopold BELLAN
-
Paris, France, 74014
- Hôpital Cochin, clinique de rhumatologie
-
Pierre Bénite, France, 69495
- CHU Lyon Sud
-
Pierre Bénite, France, 69495
- CH Lyon sud
-
Poitiers, France, 86 021
- Hopital de la Milétrie
-
Rennes, France, 35000
- CHR
-
Rouen, France, 76031
- Hôpitam de Bois Guillaume
-
Strasbourg, France, 67098
- Hôpital de Hautepierre
-
Toulouse, France, 31403
- CHU de Rangueil
-
Tours, France, 37044
- CHU Trousseau
-
Vandoeuvre les Nancy, France, 54511
- CHU de Brabois
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients fulfilling the American College of Rheumatology criteria for the diagnosis of hip osteoarthritis.
- Lequesne algofunctional index of at list 3 points.
- Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point.
Exclusion Criteria:
- Intraarticular injection or arthroscopy of the hip during the three months prior to inclusion in the study.
- Any systemic or intraarticular corticosteroid as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Joint space measurement
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Tolerability
|
|
Requirement of hip replacement surgery after ten years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: DOUGADOS Maxime, Scientific Committee
- Principal Investigator: Michel LEQUESNE, Scientific Committee
- Principal Investigator: Bernard MAZIERE, Scientific Committee
- Principal Investigator: Eric VIGNON, Scientific Committee
- Principal Investigator: Laurent BERDAH, Scientific Committee
- Principal Investigator: Minh NGUYEN
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HEC / CHO 90040N
- AFSSAPS number: 930289
- CCPPRB number: 469
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.